Download presentation
Presentation is loading. Please wait.
Published byLioba Kurzmann Modified over 5 years ago
1
Autoantigens in Vitiligo Identified by the Serological Selection of a Phage-Displayed Melanocyte cDNA Expression Library Elizabeth A. Waterman, David J. Gawkrodger, Philip F. Watson, Anthony P. Weetman, E. Helen Kemp Journal of Investigative Dermatology Volume 130, Issue 1, Pages (January 2010) DOI: /jid Copyright © 2010 The Society for Investigative Dermatology, Inc Terms and Conditions
2
Figure 1 Enrichment of the melanocyte cDNA phage display library with vitiligo patient IgG. The melanocyte cDNA phage display library was incubated with biotinylated vitiligo patient IgG. The phage–antigen–IgG complexes were captured on Dynabeads M-280 Streptavidin. Non-specifically bound and unbound phage particles were removed by washing. IgG-bound phage particles were eluted and used to infect E. coli XL1-Blue and amplified for use in further rounds of selection. Journal of Investigative Dermatology , DOI: ( /jid ) Copyright © 2010 The Society for Investigative Dermatology, Inc Terms and Conditions
3
Figure 2 Antibody (Ab) indices of vitiligo patient and control sera in radioimmunoassays. Non-segmental vitiligo patient (n=53), segmental vitiligo patient (n=8) and control (n=28) sera were analyzed in radioimmunoassays for Ab reactivity to gamma-enolase, alpha-enolase, HSP90, osteopontin, ubiquitin-conjugating enzyme (UCE), translation-initiation factor 2 (TIF2), and GTP-binding protein, Rab38, as detailed in Materials and Methods. The Ab index shown for each serum sample is the mean of at least two experiments. The upper limits of normal for each radioimmunoassay were Ab indices of gamma-enolase, 1.30; alpha-enolase, 1.40; HSP90, 1.59; osteopontin, 1.38; UCE, 1.22; TIF2, 1.23; GTP-binding protein, Rab38, S, symmetrical vitiligo patients; Seg, segmental vitiligo patients; C, healthy controls. Journal of Investigative Dermatology , DOI: ( /jid ) Copyright © 2010 The Society for Investigative Dermatology, Inc Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.